Navigation Links
Sentara begins international trial -- open at only 24 US locations
Date:9/25/2008

Norfolk, VA September 23, 2008 Researchers at Sentara Cardiovascular Research Institute begin a new international study to explore the safety and effectiveness of stents to open airways of patients with advanced emphysema or Chronic Obstructive Pulmonary Disease (COPD).

The EASE (Exhale Airway Stents for Emphysema) Trial focuses on airway bypass, an investigational technique without surgery to create new pathways to release trapped air from within diseased lung tissue, thereby helping patients with advanced widespread emphysema breathe easier.

Similar to the stents used to prop open clogged arteries in heart patients, these drug-eluting stents are now holding open new passageways in the lungs.

Pulmonologists and cardiothoracic surgeons at Sentara Thoracic Surgery Center in Norfolk, Virginia are collaborating to perform this investigational procedure of the first wave of Virginia participants. During the procedure, a tube is guided through the mouth of trial participants to access the lung and implant up to six stents smaller than a pencil eraser. The goal is to relieve breathlessness and over inflated lungs hallmarks of this incurable, progressive disease.

Traditional treatment options for patients with severe emphysema are limited to lung reduction surgery, lung transplant, and inhalers, which have diminishing impact as the disease progresses. Airway bypass, done without open surgery, is considered minimally invasive and hoped to be an option for broader numbers of patients.

"Emphysema is really life limiting. Some of my patients who golfed a year ago now get winded taking a shower," says cardiothoracic surgeon Joseph Newton, Sentara Cardiovascular Research Institute's principal investigator for this trial. "Through research like this, I'm hopeful we are going to find a way to help these patients do things most of us take for granted," he continues.

That's just what trial candidate John Woodard is hoping for. The 61-year-old Suffolk resident is being evaluated Tuesday, September 22 at Sentara to begin the enrollment process.

"I don't look sick," says Woodard. "You wouldn't know any better until you saw me exercise," continues Woodard who ran 35 miles each week up until about 10 years ago. Woodard retired a year ago because of his condition. "I still play golf, but I have to bring my oxygen with me," he says.

"Research like this gives new hope of a longer-term solution for more people. Transplant is not a practical option for a lot of people with severe emphysema," says Dr. Carolyn Fruci, pulmonologist and critical care specialist involved in the study. "What's exciting is the possibility of patients regaining some of the everyday freedoms lost to this disease," Fruci continues.

Transplant, one of the only treatments today for patients with severe emphysema, is not plausible for every patient. Participation in this trial does not prevent patients from being considered for lung transplantation at a later time.

For Woodard, who has been coping with COPD for the last 10 years, participating in this research offers hope. "I'm up for most anything. Naturally if there's any benefitto me or anybody elsethat would be wonderful," say Woodard, who is being evaluated for participation in the trial.


'/>"/>

Contact: Cheri Hinshelwood
CSHINSHE@sentara.com
757-594-1036
Broncus Technologies
Source:Eurekalert  

Related biology news :

1. Building a stronger roof over your head: 3 little pigs project begins first tests
2. 8-day undersea mission begins experiment to improve coral reef restoration
3. War between the sexes begins before twins birth, TAU researchers say
4. iPlant Kickoff Conference at CSHL begins tackling plant biologys grand challenges
5. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
6. DHS Begins Collecting 10 Fingerprints From International Visitors at New Yorks John F. Kennedy International Airport
7. DHS Begins Collecting 10 Fingerprints From International Visitors at Detroit Metropolitan Wayne County Airport
8. DHS Begins Collecting 10 Fingerprints From International Visitors at Orlando International Airport
9. DHS Begins Collecting 10 Fingerprints From International Visitors at Miami International Airport
10. DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport
11. DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Sentara begins international trial -- open at only 24 US locations
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
(Date:1/7/2016)... Various factors have contributed to the ... biologics and biosimilars. Some of these factors include ... demand for cost-effective alternatives, growing burden of chronic ... versions of their corresponding patented biologic drugs, and ... and efficacy. The global biosimilars market is estimated ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology: